46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...
Ladies and gentlemen, thank you for standing by. Welcome to Pyxis Oncology MICVO Clinical Update Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...
Pyxis Oncology, Inc. announced promising preclinical results for micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting extradomain-B fibronectin (EDB+FN). The data, to be presented at ...
Pyxis Oncology, Inc. announced that its President and CEO, Dr. Lara S. Sullivan, will participate in investor conferences, specifically the RBC Capital Markets Global Healthcare Conference on May 21 ...
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback